CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Trial ID or NCT#
NCT04088864
Status
NOT RECRUITING
Purpose
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).
Official Title
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Eligibility Criteria
Ages Eligible for Study: 1 Year to 30 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Crystal Mackall
Sneha Ramakrishna
Contact us to find out if this trial is right for you.
Contact
Amy Li
650-725-4318
View on ClinicalTrials.gov
